Aspirin, cyclooxygenase inhibition and colorectal cancer

Table 5 Clinical effects of aspirin in high risk population (clinical trials)

Study	Patients	Treatment	RR or HR (95%CI)	Ref.
CAPP1 trial	FAP young patients (10 to 21 years of age)	ASA (600 mg/d) plus placebo or resistant starch (30 g daily) plus placebo or double placebo for 17 years	RR = 0.77 (0.54-1.10), ASA vs non ASA	[22]
CAPP2 trial	Hereditary non-polyposis colon cancer or HNPCC	ASA (600 mg/d) or ASA placebo or resistant starch (30 g daily) or starch placebo for up to 4 years	HR = 0.63 (0.35-1.13), for the entire post-randomization period (ASA vs placebo) HR = 0.41 (0.19-0.86), for ≥ 2 years of treatment (ASA vs placebo)	[23]
J-FAPP II trial	FAP patients (≥ 16 years of age)	Placebo vs enteric coated ASA (100 mg/d ) for 6-10 mo	Ongoing	[25]

ASA: Aspirin; FAP: Familial adenomatous polyposis.